GLP-1
Glucagon-like peptide-1 receptor pathway.
Editor's picks.
A laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →1 guide
Related products.
Compare research compounds.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideTriple agonist vs single GLP-1 — class, mechanism and lab context.
View comparison →Side by sideSelective GLP-1 agonist vs dual GIP/GLP-1 agonist — receptor pharmacology and evidence comparison.
View comparison →Frequently asked questions.
Is retatrutide approved for human use?
No. Retatrutide is supplied strictly for laboratory research and is not approved for human or veterinary administration.
Read: What is Retatrutide? →What receptors does retatrutide act on?
In published research it has been characterised as a triple agonist acting on the GLP-1, GIP and glucagon receptors.
Read: What is Retatrutide? →How should retatrutide be stored?
Lyophilised vials are stored at 2–8°C, protected from light. Once reconstituted with bacteriostatic water, store refrigerated and use within 30 days.
Read: What is Retatrutide? →Which is the newer research compound?
Retatrutide is the more recently characterised compound in the academic literature, while tirzepatide is the more established reference.
Read: Retatrutide vs Tirzepatide →